Lv X, Tang S, Xia Y, Zhang Y, Wu S, Yang Z, Li X, Tu D, Chen Y, Deng P, Ma Y, Chen D, Chen R, Zhan S

Language: English
References: 39
Page: 700-707
PDF size: 125.68 Kb.

ABSTRACT

Background. Anti-tuberculosis drug-induced hepatotoxicity (ATDH) is one of the most prevalent and serious adverse drug reactions in the course of anti-tuberculosis (TB) treatment. Some researchers suggested that determination of N-acetyltransferase 2 (NAT2) genotype may be clinically useful to identify patients at high risk of developing ATDH. Aim. To evaluate whether the NAT2 genotype could be as a predictor for ATDH in Chinese community TB population. Material and methods. A total of 4304 community-based TB patients were followed up six to nine months prospectively. A nested case-control study was designed. Each ATDH case was 1:4 matched with controls by age (within 5 years old), gender, treatment history, disease severity and drug dosage. The polymorphisms of NAT2 were determined using polymerase chain reaction with restriction fragment length polymorphism. Conditional Logistic regression model was used to calculate odds ratio (OR) and 95% confidence interval (CI), as well as corresponding P-values. Results. A total of 89 ATDH cases and 356 controls were included in this study. Allele frequency of NAT2*5, NAT2*6 and NAT2*7 in cases and controls were 4.5 and 3.2%, 25.3 and 26.5%, and 13.5 and 13.5%, respectively. Frequencies of genotypes and alleles of NAT2*5, NAT2*6 and NAT2*7 did not differ significantly between cases and controls. The OR of intermediate acetylator and slow acetylator compared with rapid acetylator was 1.040 (95%CI 0.616-1.758) and 0.990 (95%CI 0.509-1.925), respectively. The NAT2 haplotype distribution in cases was similar to controls. Conclusions. In conclusion, we did not find significant association between NAT2 genotype and ATDH in community-based Chinese population. It may be deficient to take NAT2 genotype as a predictor for ATDH in Chinese community TB patients.

REFERENCES

1. Awofeso N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ 2008; 86: B-D.

2. Kaona F, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 2004; 4: 68.

3. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202.

4. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.

5. Xia YY, Zhan SY. Systematic review of anti-tuberculosis drug induced adverse reactions in China. Chin J Tuberc Dis 2007; 30: 419-23.

6. Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4: 83-113.

7. Sunahara S, Urano M, Ogawa M. Genetical and geographic studies on isoniazid inactivation. Science 1961; 10: 1530-1.

8. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9: 29-42.

9. Roy B, Ghosh SK, Sutradhar D, Sikdar N, Mazumder S, Barman S. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatricpatients. J Gastroenterol Hepatol 2006; 21: 784-6.

10. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP. Increased risk of antituberculosis druginduced hepatotoxicity in individuals with glutathione Stransferase M1 ‘null’ mutation. J Gastroenterol Hepatol 2001; 16: 1033-7.

11. Singh J, Garg P, Thakur VS, Tandon RK. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter? Indian J Physiol Pharmacol 1995; 39: 43-6.

12. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-9.

13. Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010; 14: 622-6.

14. Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, Kim YS, et al. Genetic polymorphism of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009; 10: 1767-79.

15. Wang PY, Xie SY, Zhang GW, Hao Q. Prospective nested case-control study on relation between N-acetyltransferase-2 acetylator phenotype and hepatotoxicity in China. Chin J Public Health 2009; 25: 300-2.

16. An HR, Wu XQ, Wang ZY, Liang Y, Zhang JX. The associations of polymorphism of N-acetyltransferase 2 gene is associated with antituberculosis drug-induced hepatotoxicity in tuberculosis patients. Zhonghua Yu Fang Yi Xue Za Zhi 2011; 45: 36-40.

17. Wu YM, Luo ZY, Zhang HM, Peng JF, Liu SY, Wang M. The association between NAT2 polymorphism and antituberculosis drug-induced hepatitis. Zhonghua Gan Zang Bing Za Zhi 2010; 18: 467-9.

18. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH, Kim JW, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87: 551-6.

19. Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyltransferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26: 312-8.

20. Higuchi N, Tahara N, Yanagihara K, Suyama N, Inoue Y, Miyazaki Y, Kobayashi T, et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 2007; 13: 6003-8.

21. Bozok Cetintas V EO, Kosova B, Ozdemir I, Topcuoqlu N, Eroqlu Z. Determining the relation between N-acetyltransferase- 2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks 2008; 56: 81-6.

22. Mihaljeviæ-Peles A, Sagud M, Bozina N, Zivkoviæ M, Jovanoviæ N. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy. Psychiatr Danub 2010; 22: 335-7.

23. Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, Fogar P, Nisi A, et al. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics 2011; 12: 15-25.

24. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009; 13: 1-9.

25. Xia YY. Antituberculosis Drugs Induced Adverse Reactions in China National Tuberculosis Prevention and Control Scheme Study. Beijing: Peking University Health Science Center; 2011, p. 26-28.

26. Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, Tu DH, et al. Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). BMC Public Health 2010; 10: 267.

27. Lin HJ, Han CY, Hardy S. Slow aceytlator mutations in the human polymorphic N acetyltransferase gene in 786 Asians, blacks, Hispanics, and Whites: Application to metabolic epidemiology. Am J Hum Genet 1993; 52: 827-34.

28. World Health Organization: The use of the WHO-UMC system for standardized case causality assessment. Uppsala: The Uppsala Monitoring Centre; 2005.

29. Benichou C. Criteria of drug induced liver disorders: reform of international consensus meeting. J Hepatol 1990; 11: 272-6.

30. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66: 758-66.

31. Zieliñska E, Niewiarowski W, Bodalski J, Rebowski G, Skretkowicz J, Mianowska K, Sekulska M. Genotyping of the arylamine N-acetytransferase polymorphism in the prediction of idiosyncartic reactions to trimethoprim-sulfamethoxazole in infants. Pharm World Sci 1998; 20: 123-30.

32. Xie HG, Xu ZH, Ou-Yang DS, Shu Y, Yang DL, Wang JS, Yan XD, et al. Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 1997; 7: 503-14.

33. Leiro-Fernandez V, Valverde D, Vázquez-Gallardo R, Botana- Rial M, Constenla L, Agúndez JA, Fernández-Villar A. Nacetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis 2011; 15: 1403-8.

34. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-51.

35. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of Drug-Induced Liver Injury. Hepatology 2010; 52: 748-61.

36. Fernández-Villar A, Sopeña B, Fernández-Villar J, Vázquez- Gallardo R, Ulloa F, Leiro V, Mosteiro M, et al. The influence of risk factors on the severity of antituberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8: 1499-505.

37. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-30.

38. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, Lee SD. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47: 128-34.

39. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-9.